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Venous thromboembolism (VTE) is a major cause of morbidity and mortality. The 
impact of the Surgeon General’s Call to Action in 2008 has been lower than expected 
given the public health impact of this disease. This scientific statement highlights 
future research priorities in VTE, developed by experts and a crowdsourcing survey 
across 16 scientific organizations. At the fundamental research level (T0), researchers 
need to identify pathobiologic causative mechanisms for the 50% of patients with 
unprovoked VTE and better understand mechanisms that differentiate hemostasis 
from thrombosis. At the human level (T1), new methods for diagnosing, treating, and 
preventing VTE will allow tailoring of diagnostic and therapeutic approaches to in-
dividuals. At the patient level (T2), research efforts are required to understand how 
foundational evidence impacts care of patients (eg, biomarkers). New treatments, 
such as catheter-based therapies, require further testing to identify which patients 
are most likely to experience benefit. At the practice level (T3), translating evidence 
into practice remains challenging. Areas of overuse and underuse will require evi-
dence-based tools to improve care delivery. At the community and population level 
(T4), public awareness campaigns need thorough impact assessment. Large popula-
tion-based cohort studies can elucidate the biologic and environmental underpinings 
of VTE and its complications. To achieve these goals, funding agencies and training 
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programs must support a new generation of scientists and clinicians who work in mul-
tidisciplinary teams to solve the pressing public health problem of VTE.
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Essentials
• The article presents future research priorities in venous thromboembolism.
• It was developed by experts and a crowdsourcing survey across 16 scientific organizations.
• It covers fundamental (T0), human-level (T1), patient-level (T2), practice-level (T3), and community- and population-level (T4) research.
• The authors suggest that multidisciplinary team science approaches be prioritized.
1  | INTRODUCTION
Venous thromboembolism (VTE) remains a major cause of morbid-
ity and mortality, affecting up to 1 million Americans and more than 
700 000 Europeans annually.1 Composed of both deep vein throm-
bosis (DVT) and pulmonary embolism (PE), VTE disproportionately 
impacts older adults worldwide.2 An estimated 1-in-12 people will 
develop VTE after age 45.3 Thirty-day mortality is as high as 30% 
for patients with PE.4 Emerging knowledge suggests that impaired 
quality of life is common. Up to 50% of patients with DVT will de-
velop postthrombotic syndrome (PTS), which consists of pain, swell-
ing, skin changes, and ulceration; 5%-10% will have severe morbidity 
with reduced quality of life.5
In 2008, the US surgeon general issued a call to action to prevent 
DVT and PE.6 That document highlighted the unique opportunity for 
multiple stakeholders to coordinate efforts aimed at (i) increasing 
public awareness, (ii) supporting development of evidence-based 
practices, and (iii) carrying out research to address gaps in knowl-
edge. It is unclear how much progress has been made in the decade 
since that call to action. While some organizations champion patient, 
provider, and public awareness, efforts in translational and transfor-
mative research are not commensurate with the public health impact 
of VTE.7
This statement outlines key research priorities to address 
knowledge gaps in VTE (Table 1). As outlined in Supplements S1 
and S2, in 2018, members of 16 international organizations, includ-
ing lead organizations for this project (American Heart Association, 
American Venous Forum, and ISTH) were invited in a crowdsourcing 
activity to share their priorities for VTE research through a survey. 
While attempts were made to include a global perspective, we did 
not collect participant location, and North American participation 
may be overrepresented. Informed by these results, invited experts 
presented their vision at the 2018 American Heart Association 
Vascular Discovery conference (San Francisco, CA), and the audi-
ence provided input. At that meeting, a writing group was formed 
to develop this scientific statement based on survey results. The 
final manuscript outlines key areas for future research across the 
spectrum of translational research (bench-to-bedside-to-popula-
tion; Figure 1). As this article was going to production, the rapid 
realization of a new coagulopathy with marked VTE risk related to 
coronavirus disease 2019 has led to pressing need for basic, trans-
lational, and clinical research, including on antithrombotic treat-
ments in these patients.
2  | T0 – FUNDAMENTAL RESEARCH: FROM 
MOLECULES TO BIOLOGICAL SYSTEMS
Most of the time, the coagulation system remains well balanced to 
respond to vascular injury without clotting within the vessels (hemo-
stasis). However, when clot formation does occur within blood ves-
sels (thrombosis), the effects are life threatening. Mechanisms that 
differentiate clot formation occurring in the setting of hemostasis 
versus those that promote thrombosis remain poorly understood. 
The fact that up to half of VTE cases lack an identifiable provoking 
trigger highlights a critical knowledge gap regarding the mechanisms 
that drive pathological thrombus formation.
A persistent gap in developing new approaches to treat and pre-
vent VTE is inadequate understanding of the underlying pathophys-
iology. Virchow's triad of abnormalities in blood components, the 
vessel wall, and blood flow defines our understanding of thrombotic 
risk and provides a platform for fundamental and discovery-based 
research into the mechanisms driving VTE. Researchers have largely 
taken a deconstructive approach focused on each component in iso-
lation to determine its independent contribution to thrombus for-
mation. Although these studies have defined numerous mechanisms 
regarding blood components and their role in VTE,8 effects of vascu-
lar wall dysfunction and blood flow on physiological and pathological 
clot formation are still not well characterized. For example, genetic, 
biochemical, and animal studies of plasma clotting factors have ro-
bustly associated abnormal levels of certain plasma proteins with VTE 
risk.9 However, the fact that many patients with these abnormalities 
do not develop VTE indicates that additional, coexisting abnormali-
ties of thrombosis, vessel wall dysfunction, or environmental factors 
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are necessary to promote thrombosis. Understanding the complex 
interactions within VTE risk factors is a driving need in VTE research.
In VTE, as in any thrombotic disease, pathological cross-talk be-
tween the vessel wall and blood components is considered a driver of 
thrombosis. This complex scenario is difficult to reproduce in a labora-
tory setting. Over the years, the scientific community has recognized 
the importance of both in vitro (eg, cell coculture, microfluidic, and 
computational models) and in vivo (eg, vena cava ligation, FeCl3 injury) 
preclinical models to understand thrombosis and evaluate potential 
treatments. All current VTE preclinical models have pros and cons. 
Understanding these strengths and limitations is imperative when 
choosing models in the context of a given research question.
Given the strength that in vivo models can simultaneously incorpo-
rate all 3 arms of Virchow’s triad, animal research has become an essen-
tial tool in efforts to define pathophysiologic mechanisms in VTE and has 
significantly advanced understanding of cellular and biochemical mech-
anisms. However, live models have their limitations based on species, 
size, and life span. These differences can limit their application to the 
human experience of VTE. For example, most PE models do not repli-
cate the human experience where a DVT embolizes from the deep veins 
to the lungs. Instead, they commonly rely on protein infusion locally 
to incite thrombosis. Developing new models that more closely mimic 
human pathobiology (including embolism) is a high priority given PE-
related mortality and differences in DVT- and PE-specific risk factors.10
3  | T1 – TRANSLATIONAL RESEARCH: 
FROM ANIMALS TO HUMANS
Significant advances in diagnosing, treating, and preventing VTE 
depends on translating fundamental and discovery-based research 
findings to humans (T1 research). A high priority in diagnosis of VTE 
is elucidating thrombus chronicity or embolic potential with imaging 
that incorporates information on thrombus pathophysiology. This 
might improve diagnostic accuracy and influence treatment deci-
sions. For example, a lower-extremity thrombus with imaging char-
acteristics that suggest low embolic potential may be safely treated 
with shorter courses of anticoagulation, while one with higher em-
bolic potential may warrant longer courses of anticoagulation or 
the placement of an inferior vena cava filter if anticoagulation is 
contraindicated.
The emergence of direct oral anticoagulants (DOACs) has trans-
formed VTE treatment; however, the search continues for even safer 
treatments.11 Recent epidemiological studies and animal models show 
relationships between a number of cloting factors (eg, factors XIa, XII, 
and IX) and VTE suscepibility. For example, factor XIa inhibition is emerg-
ing as a promising therapeutic strategy with the potential of limited 
bleeding complications.12 While various factor inhibitor agents move 
through the clinical trials pipeline, carefully designed studies should con-
currently identify optimal treatment strategies based on patient and VTE 
charactersitics.
Independent of therapy choice, identifying patients at greatest 
risk for recurrent VTE, who might benefit from long-term secondary 
TA B L E  1   Some research priorities in venous thromboembolism 
across the spectrum of translational research
T0 – Fundamental and discovery-based research
• Uncover mechanistic differences between hemostasis and 
thrombosis
• Specify individual and interacting roles for cellular, biochemical, 
and biophysical (flow) functions and thrombogenesis
• Explore effects of vascular wall dysfunction and blood flow on 
thrombus formation
• Develop robust animal models of PE that mimic human disease
• Understand limitations and appropriate use of specific VTE 
preclinical models
• Distinguish mechanisms of in situ thrombosis versus embolization
T1 - Human level research
• Develop imaging tools for diagnosis that characterize thrombus 
chronicity and embolic potential
• Identify new targets for anticoagulant therapies
• Combine imaging findings with biomarkers (circulating factors, 
genomics, etc) to identify populations most likely to benefit from 
VTE prophylaxis or treatment
• Identify the role of novel biomarkers to predict VTE recurrence 
risk
• Explore the efficacy of VTE treatment strategies based on 
thrombus characteristics instead of duration
T2 - Patient level research
• Identify patients most likely to benefit from catheter-based 
therapies in both PE and proximal DVT
• Explore the role of adjuvant therapies (eg, statins, P2Y12 
inhibitors) to prevent postthrombotic syndrome
• Identify causes of “breakthrough” VTE despite adequate 
prophylaxis
• Improve prediction and understand clinical course of VTE in 
pediatric populations
• Define thresholds for VTE prophylaxis and appropriate dosing in 
those at risk of VTE, including pregnant patients
T3 - Practice level research
• Study methods to better implement VTE trial evidence into 
clinical practice, including both overuse and underuse of VTE-
specific therapies
• Explore the role of the electronic medical record and population 
health tools intended to drive appropriate clinical care
• Study effectiveness of devices for PE and DVT treatment (ie, 
vena cava filters, thrombus retrievers, etc) using population-
based registries
• Define the safety and efficacy of DOAC therapy in special 
populations
• Define the clinical and nonclinical impacts of thrombophilia 
testing in patients, their families, and the population at large
T4 - Community and population level research
• Assess the impact of public awareness campaigns about VTE on 
disease detection, prevention, and treatment
• Conduct large population-based studies to explore biologic and 
environmental underpinnings of VTE along with their patient-
oriented nonthrombotic outcomes (highlighted in Supplemental 
Material)
• Perform population-based studies to examine patient-centered 
outcomes, including long-term symptoms, functional status, and 
the consequent effects on quality of life
• Define the impact of VTE on economic and health status 
measures across different populations
• Determine the effect of health care delivery on the variation in 
VTE outcomes
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prevention, remains a challenge.6 Research on defining treatment 
duration that extends beyond consideration of presenting char-
acteristics (eg, provoked versus unprovoked VTE) is warranted. 
Significant progress in this area may be possible using innova-
tive imaging and biomarker assessments. Biomarkers other than 
D-dimer that predict VTE recurrence risk are needed; candidates 
include soluble P-selectin, factor VIII, factor IX, extracellular DNA, 
and intercellular adhesion molecule 1, but new biomarkers should 
be sought.13,14 High-resolution imaging and proteomic analysis of 
thrombi may provide new mechanistic biomarkers of recurrence.15 
Other avenues to pursue include genetic screening, which is com-
plicated by epigenetic factors that also contribute to disease.16 
Unbiased “omics” approaches that measure circulating microRNAs 
has identified candidates that are associated with VTE recurrence.17 
Metabolic screening has also shown potential to identify new bio-
markers that influence VTE.18,19 In sum, personalized approaches 
to treatment that integrate thrombus pathophysiology, circulating 
biomarkers, patient characteristics, and patient preferences require 
study.20
4  | T2 – CLINICAL RESEARCH: FROM 
HUMANS TO PATIENTS
Clinicans struggle to translate findings from discovery-based re-
search to care of individual patients (T2 research). For example, 
selecting therapies based on VTE recurrence risk remains a largely 
unfulfilled goal. As noted above, the use of new biomarkers may 
offer “personalization” opportunities in VTE treatment. However, 
challenges remain in translating the findings from T0 and T1 re-
search to large cohorts that can account for the heterogeneity in 
populations while assessing if specific therapies influence clot struc-
ture in a manner that impacts clinical outcome.21
Catheter-based therapies, including thrombolysis, are increas-
ingly used for patients with acute PE and/or DVT. Determining pa-
tients most likely to benefit from an invasive procedure is needed.22 
At the same time, clinical, biomarker, and echocardiographic param-
eter collection (in PE) is necessary for prospective validation of many 
different risk stratification tools.
The impact of therapy on long-term outcomes is not well de-
scribed. For example, while pharmacomechanical thrombolysis may 
not prevent PTS after proximal DVT in general, efficacy in selected 
patients based on anatomic presentation and persistence of symp-
toms despite anticoagulation is unknown. The same is true for use 
of catheter-based therapies in patients with intermediate- and high-
risk PE to prevent long-term dyspnea and fatigue associated with the 
so-called post-PE syndrome.
Few modalities have demonstrated benefit in preventing PTS 
in patients with DVT. Specifically, compression stockings failed to 
prevent PTS in at least 1 large randomized study.23 However, other 
treatments to prevent PTS merit study, including different antico-
agulant strategies, P2Y12 inhibitors, adhesion molecule inhibitors, 
venoactive drugs, and statins. Finally, limited research is available on 
effective treatment of PTS, including the roles of the above medica-
tions and venous surgical interventions.
Optimizing VTE prevention in hospitalized medical and sur-
gical patients can reduce the population burden of VTE. Several 
questions require research: identification of patients at highest 
risk of VTE and bleeding to guide prophylaxis type and duration; 
understanding why “breakthrough” VTE occurs in hospitalized 
patients receiving prophylaxis; identification of methods to en-
hance compliance with prophylaxis24,25; and methods to reduce 
overuse of prophylaxis, which is both costly and potentially 
dangerous. Studies of deimplementation that reduce overuse of 
therapies (eg, VTE prophylaxis in low-risk patients) are equally 
important.
F I G U R E  1   Priorities for future VTEresearch across the translational spectrum. VTE, venous thromboembolism; T0 indicates fundamental 
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Finally, management of VTE in pediatric and pregnant patients 
remains understudied. The incidence of VTE in pediatric patients is 
low.26 Harnessing a multicenter consortium to pool standardized an-
atomic, therapeutic, and demographic data with long-term follow-up 
may further define the clinical course of VTE in children. VTE in preg-
nancy is a highly morbid complication. While low-molecular-weight 
heparin is standard of care for prophylaxis in high-risk women, major 
gaps remain in assessing the absolute VTE risk, selecting dose, and 
determining duration of prophylaxis,27,28 and in optimal treatment 
when VTE occurs in pregnant women.
5  | T3 – TRANSLATIONAL RESEARCH: 
FROM PATIENTS TO CLINICAL PRACTICE
While large-scale clinical trials can establish the efficacy of vari-
ous interventions (both prophylactic and treatment), implement-
ing these into clinical practice (T3 research) remains a barrier 
to improved health. Important aspects of evidence-to-practice 
translation are both the overuse and underuse of treatments. 
Examples of overuse include placement of inferior vena cava fil-
ters for primary prophylaxis in patients at risk for VTE and use 
of catheter-directed thrombolysis for treating patients with in-
termediate- and high-risk PE without randomized trial evidence 
supporting mortality benefits.29-31 Examples of underuse in-
clude differential DOAC prescribing and low use of outpatient 
DVT treatment based on race and socioeconomic factors.32,33 
Tools (eg, prediction models) are needed to help clinicians se-
lect patients most likely to benefit from specific interventions. 
Integrating these into the electronic medical record may improve 
safe medication delivery. Additionally, identification of strategies 
aimed at changing clinician behavior to adopt evidence-based 
practices are critically important.
The rapid growth in use of devices (eg, vena cava filters, venous 
stents, thrombolysis, and thrombectomy catheters) to treat patients 
with VTE presents a clinical dilemma. Devices often achieve regu-
latory approval based largely on safety profile, while randomized 
controlled trials comparing these devices to noninterventional ap-
proaches and between different devices are needed to determine 
clinical efficacy. Also, postmarketing assessment of device utiliza-
tion, efficacy, and safety is needed. Well-designed population-based 
registries can play a role in determining the profile of patients in 
which these devices are being used, what clinical benefits can be 
expected, which patients are more likely to experience benefit, and 
what risks are associated with use of the devices outside of research 
settings.
While each of the DOACs have undergone large-scale trials, 
some populations were inadequately represented, and race/eth-
nicity of trial participants was not always diverse. Notable ex-
amples of other under-represented groups include patients with 
severe renal impairment or who are receiving hemodialysis, those 
at extremes of weight, those with reduced absorption due to gas-
trointestinal surgery, those with autoimmune diseases, and those 
who have had venous stenting procedures.34,35 High-quality ef-
ficacy and safety data for DOAC use in cerebral and portal ve-
nous thrombosis is also lacking. Since it is impractical to conduct 
randomized trials in each of these patient groups, observational 
studies are needed to further assess safety and efficacy.
Finally, many inherited and acquired thrombophilias can be di-
agnosed in patients with VTE, and some increase risk of recurrence 
after a first event. However, only D-dimer has been adequately 
studied for guiding management decisions, and little is known on 
the overall health impact and economics of thrombophilia testing, in 
both patients and their relatives. More work is needed to understand 
the benefits and harms of genetic and nongenetic thrombophilia 
testing and how best to integrate that information into management 
and prevention.
Across a range of treatment modalities, better equipping physi-
cians and health care systems to translate evidence into practice is 
needed. This includes identifying subpopulations most likely to ben-
efit from therapies, exploring therapeutic benefits in populations 
not typically included in randomized trials, and understanding the 
impact of diagnostic testing on care at the practice and population 
levels for patients with VTE.
6  | T4 – GLOBAL RESEARCH: 
FROM CLINICAL PRACTICE TO 
HEALTHCARE SYSTEMS
Public awareness and public health efforts to address VTE pre-
vention and treatment have a limited evidence base (T4 research). 
Despite VTE being a common disease, few in the public are aware 
of its signs, symptoms, and risk factors.36 Campaigns such as World 
Thrombosis Day, initiatives from the American Heart Association, 
and other efforts may increase awareness, but more studies are 
needed to gauge improvement in public knowledge based on these 
programs.
Analogous to research efforts in atherosclerosis, large popula-
tion-based epidemiology studies are needed to better understand 
the biologic and environmental causes of VTE, and the range of 
nonthrombotic outcomes in patients who have experienced VTE 
(described in Supplements S1 and S2). Data from these studies 
could generate hypotheses on causal mechanisms of VTE and be 
harnessed to design clinical trials of preventive and therapeutic 
treatments that precisely target genetic, molecular, clinical, and/or 
environmental mechanisms associated with VTE and its recurrence. 
These studies would include collection of blood and tissue samples 
for storage in biorepositories for subsequent analysis. Information 
ranging from genomics, transcriptomics, proteomics, and metabo-
lomics would be integrated with demographic, clinical, laboratory, 
imaging information, and exposures (including socioeconomic and 
other environmental characteristics) to create large databases that 
could be shared. Outcomes after VTE for conditions that share risk 
factors with VTE (eg, kidney disease) and psychosocial outcomes 
after VTE (eg, depression) are poorly understood.
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Up to 50% of patients develop long-term exercise limitation after 
PE or the PTS following DVT.37,38 Yet the effect of DVTs and PEs 
on long-term health status and societal impacts for many of those 
afflicted is not well established. More population-based studies are 
needed to examine patient-centered outcomes, including long-term 
symptoms, functional status, and consequent effects on quality of 
life.39 These studies should use or develop disease-specific mea-
sures whenever possible.37,40-42 Furthermore, studies are needed to 
determine best methods for integrating traditional methods of col-
lecting patient-reported quality of life outcomes along with digital 
health tools, such as wearable sensors, smartphones, and point-of-
care devices that monitor biometrics.43,44
Population-based studies are needed to determine the effect of 
health care delivery on VTE outcomes. These include comparative 
effectiveness studies assessing clinical and economic end points and 
studies addressing implementation of evidence-based practices (eg, 
VTE risk assessment and prophylaxis in hospitalized patients). Given 
the well-documented disparities in health and health care in minority 
populations in the United States, the latter related to access and 
outcomes, special attention should be afforded to those populations 
to address specific predilections and outcomes in those with VTE. 
This research could involve analysis of data from electronic health 
records, observational registries, and insurance and administrative 
claims databases, which would enable assessment of how nonclini-
cal factors like education, income, insurance coverage and payment 
policies, and governmental regulations influence diffusion and up-
take of effective therapies to affect mortality and morbidity from 
VTE, and the quality of life of patients affected by VTE.45 There is an 
unmet need to define and study similar disparities in other countries.
7  | IMPORTANCE OF 
INTERDISCIPLINARY APPROACHES
The VTE research field needs answers, and the answers cannot 
come from one single research tool. Collaboration among experts 
in each preclinical and clinical area will provide optimal insight to 
the field and to the patients, the ultimately beneficiary of our daily 
efforts.
We propose multidisciplinary approaches that integrate epide-
miologic, genomic, cellular, biochemical, and biophysical strategies 
to advance fundamental understanding and translate knowledge to 
patient care.
Practical methods to study multiple risk factors in concert lag, in 
part from the complexity of investigations involving multidisciplinary 
concepts. These studies often require harmonization of complicated 
and field-specific language to describe technically challenging meth-
ods and detailed findings. However, efforts to bridge these gaps 
and strengthen collaborations are likely to yield new information on 
pathophysiologic mechanisms. For example, a recent approach to 
combine in vivo and in vitro analyses with computational modeling 
and bioengineered microfluidic chambers revealed effects of ele-
vated hematocrit on platelet accumulation within thrombi that were 
not appreciable in mouse models alone, demonstrating the power 
of interdisciplinary collaborations.46 Accordingly, additional multi-
disciplinary studies to elucidate mechanisms in VTE are warranted. 
Devices permiting control of fluid mechanics may enable more con-
trolled studies of the contribution of blood flow than is possible 
in mice. Studies using biologically engineered “blood vessels” with 
innovative designs may expose vascular responses to changes in 
flow, as well as interactions between blood cells and proteins with 
the vessel wall during DVT.47 Similarly, integrating approaches in 
genomics and epidemiology with functional analysis of molecular 
mechanisms may define additional pathways that contribute to VTE. 
This kind of integrated approach may alleviate confounding “noise” 
in genetic analysis and provide specific and focused hypotheses to 
guide biological and biochemical studies in new directions. Pathways 
identified and characterized through these collaborations may pro-
vide robust new therapeutic targets and translate genetic discovery 
to practical applications in the clinic. Facilitating multidisciplinary 
science teams via specific funding mechanisms is a major priority for 
advancing in VTE research.
8  | BARRIERS AND OPPORTUNITIES
To solve the problems outlined above, we need to bring together 
scientists and clinicians from disparate disciplines, including those 
not traditionally involved in VTE research. For example, at the in-
tersection of rehabilitation science, epidemiology, clinical investiga-
tion, health services research, and big data sits an opportunity to 
explore the prevalence, impact, and potential therapies of the post-
PE syndrome.
While progress is being made in prevention and treatment 
of cancer-associated VTE, many questions across the transla-
tional spectrum remain. These include mechanistic, preventative, 
and therapeutic questions about this high-mortality condition. 
Multidisciplinary teams may employ different approaches to better 
understand the etiology, prevention, and treatment of cancer-asso-
ciated VTE as a distinct entity from non–cancer-associated VTE.
The broad adoption of electronic health records presents an op-
portunity to gather large quantities of data for retrospective analysis 
and to screen for patient enrollment in research studies. However, 
without improvements in quality and availability of natural language 
processing in electronic health records, much of the data stored 
is not easily searchable, presenting a major barrier to innovation. 
Additionally, challenges with interoperability between health sys-
tems and electronic health record platforms stifles potential large-
scale studies and collaborative efforts.
9  | CONCLUSION
As a leading cause of death and disability, efforts to improve the 
prevention, diagnosis, and management of VTE are vitally impor-
tant. Across the spectrum of translational research, opportunities 
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exist to transform the care of patients with VTE. New scientists 
who become invigorated to explore these high-need areas will 
have a tremenous impact on the population’s health. It is impera-
tive that funding agencies and training programs support the next 
generation of scientists who will solve many of these pressing 
public health problems.
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